Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.49 |
| ▸ | PI4KA | P42356 | 11/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 11/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 11/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580610 | 0.84 | ADORA2A (0.64) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL6036330 | 0.83 | CDK1 (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28413958 | 0.82 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2120550 | 0.82 | FDPS (0.45) | EGFR | |
| SCHEMBL3506547 | 0.81 | ADORA2A (0.46) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28553166 | 0.81 | PI4KA (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28410735 | 0.81 | ADORA2A (0.60) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL731404 | 0.81 | CYP2C9 (0.36) | ADORA2AADORA1 | |
| SCHEMBL1820741 | 0.81 | FDPS (0.35) | — | |
| SCHEMBL6959953 | 0.81 | FDPS (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 433 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115666593-A | Therapeutic agent for epithelial cancer | 国立大学法人大阪大学 | 2023-01-31 | — | — | CN | claimed |
| US-6531581-B1 | When incorporated into hairpin oligonucleotides these quench the fluorescence of fluorophores linked to the 5'-terminus of the oligonucleotide | SEROLOGICALS, INC. | 2003-03-11 | — | — | US | claimed |
| US-20240226275-A1 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | RNAimmune, Inc. (US) | 2024-07-11 | — | — | US | disclosed |
| CN-118302181-A | Multigang TP53 and PAN-RAS mRNA cancer vaccine | 达冕生物有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4388017-A1 | COMPOSITIONS AND METHODS FOR ANTI-VIRUS CHIMERIC ANTIGEN RECEPTOR | Rudd, Christopher E. (CA) | 2024-06-26 | — | — | EP | disclosed |
| EP-4384214-A2 | COMPOSITION AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | Rnaimmune, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11999995-B2 | Methylome profiling in animals and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-04 | — | — | US | disclosed |
| CN-118119930-A | Compositions and methods for mRNA vaccines against novel coronavirus infection | 达冕生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240156947-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RNAimmune, Inc. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024097259-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RNAimmune, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097894-A1 | COMPOSITIONS AND METHODS OF RIBONUCLEIC ACID VACCINES ENCODING NYE-SO-1 | RNAimmune, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-0427799-A1 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE. | GENSIA PHARMA (US) | 1991-05-22 | — | — | EP | disclosed |
| US-5008251-A | Method of treating autism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-04-16 | — | — | US | disclosed |
| WO-1991004032-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | GENSIA PHARMACEUTICALS, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
| WO-1990009163-A2 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | GENSIA PHARMACEUTICALS, INC. (US) | 1990-08-23 | — | — | WO | disclosed |
| US-4912092-A | Prevent tissue damage; administering purine nucleoside | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-03-27 | — | — | US | disclosed |
| WO-1989000854-A1 | METHODS FOR INCREASING EXTRACELLULAR ADENOSINE AND FOR STABILIZING MAST CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-02-09 | — | — | WO | disclosed |
| EP-0301900-A2 | L'utilisation de riboside ou ribotide de l'AICA pour la fabrication d'un médicament contre la crise cardiaque ou l'infarctus du myocarde aux patients souffrant d'athérosclerosis. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-02-01 | — | — | EP | disclosed |
| EP-0270885-A1 | Synthesis of purin-9-ylalkylenoxymethyl phosphonic acids | Bristol-Myers Squibb Company (US) | 1988-06-15 | — | — | EP | disclosed |
| US-4713328-A | DIAGNOSIS OF INFECTION USING BETA-LACTAMASE | RAPIDEX LIMITED, 8402 THORNDEN TERRACE, BETHESDA, MD. 20034 A CORP. OF | 1987-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156947-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RBM22, RNGTT, RBM25 | ADORA2A 2677/4885ADORA1 3667/4885PI4KA 4029/4885 |
| US-20240226275-A1 | COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | RNGTT, SARS1, ACE2 | ADORA2A 3869/4885ADORA1 4244/4885PI4KA 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.